Isotope supply gets a manufacturing fix
UK deep tech company StandardX has raised £10m in seed funding, led by Vsquared Ventures and East X Ventures, to build what it calls the world's first scalable isotope refinery.
The London-headquartered firm says its accelerator-based system can manufacture a full portfolio of isotopes at commercial scale from a standard industrial footprint — a direct response to a supply chain that is currently fragmented and reliant on ageing infrastructure.
For manufacturers, there is a real pinch point here: isotope shortages have already paused or delayed clinical trials for targeted alpha therapies across the UK and Europe.,
StandardX plans to supply its first isotopes to a medical research partner in 2027, with industrial-scale production targeted from 2029.
Longer term, the same platform is earmarked for tritium production to support fusion energy developers — a reminder that critical materials manufacturing is increasingly a cross-sector play.
Cold chain intelligence consolidates
Compression and controls giant Copeland has completed its acquisition of Dickson, a Chicago-based environmental monitoring and compliance technology provider serving regulated life sciences and healthcare environments.
The deal combines Dickson's cloud-native monitoring platform with Copeland's controls and enterprise software, aimed at giving manufacturers continuous visibility from production through to patient delivery.
With regulatory scrutiny of temperature-sensitive product handling only increasing, this consolidation move is worth watching: it signals that investment is shifting toward end-to-end cold chain compliance rather than point-solution monitoring.
UK distribution changes hands
Duke Street has sold Kent Pharmaceuticals, a speciality and generic pharmaceuticals distributor and a top supplier of injectables to UK hospitals, to Phoenix Labs, expanding the Irish player's UK footprint.